What the trial was testing
The trial enrolled 221 patients with atopic dermatitis. The study was sponsored by Celgene and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
84% reduction in eczema severity scores with the highest dose vs. 63% with placebo.
JAMA dermatology · 2024 · NCT04800315
These findings — that high-dose injection cut eczema severity scores 84% over 16 weeks vs. 63% for placebo — were published in the JAMA dermatology and represent the headline result of the study.
Researchers tracked outcomes across 221 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This early-stage study shows the injection significantly improved moderate to severe eczema that wasn't controlled by creams alone. The treatment was generally well-tolerated with manageable side effects. This is not yet FDA-approved — ask your doctor about other available options or whether you might qualify for ongoing trials.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open atopic dermatitis trials
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry
The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualified healthcare provider. Longitudinal data are collected from both subjects and their treating provider during routine clinical encounters using a structured and standardized data collection method